Latest Articles
The association between endometrial polyps and insulin resistance from the expression of PI3K and AKT proteins perspective - BioMed Central
The association between endometrial polyps and insulin resistance from the expression of PI3K and AKT proteins perspective BioMed Central
Published: June 22, 2024, 7 a.m.
ASCO 2024: New Insights Into Endometrial Cancer Treatment and Etiology - Cancer Therapy Advisor
ASCO 2024: New Insights Into Endometrial Cancer Treatment and Etiology Cancer Therapy Advisor
Published: June 20, 2024, 7 a.m.
AstraZeneca mAb Approved by FDA for Endometrial Cancer Patients - BioPharm International
AstraZeneca mAb Approved by FDA for Endometrial Cancer Patients BioPharm International
Published: June 20, 2024, 7 a.m.
The spectrum of oestrogen receptor expression in endometrial carcinomas of no specific molecular profile - Wiley Online Library
The spectrum of oestrogen receptor expression in endometrial carcinomas of no specific molecular profile Wiley Online Library
Published: June 18, 2024, 7 a.m.
AstraZeneca Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer - Reuters
AstraZeneca Imfinzi plus chemotherapy gets US nod for certain type of endometrial cancer Reuters
Published: June 17, 2024, 7 a.m.
AstraZeneca lands narrow Imfinzi nod in endometrial cancer. Where’s Lynparza? - FiercePharma
AstraZeneca lands narrow Imfinzi nod in endometrial cancer. Where’s Lynparza? FiercePharma
Published: June 17, 2024, 7 a.m.
AstraZeneca Imfinzi regimen for endometrial cancer gains FDA approval - Pharmaceutical Technology
AstraZeneca Imfinzi regimen for endometrial cancer gains FDA approval Pharmaceutical Technology
Published: June 17, 2024, 7 a.m.
AstraZeneca’s Imfinzi regimen granted FDA approval to treat endometrial cancer - PMLiVE
AstraZeneca’s Imfinzi regimen granted FDA approval to treat endometrial cancer PMLiVE
Published: June 17, 2024, 7 a.m.
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer - Pharmaceutical Executive
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer Pharmaceutical Executive
Published: June 17, 2024, 7 a.m.
Interleukin-1β induces and accelerates human endometrial stromal cell senescence and impairs decidualization via the c-Jun N-terminal kinase pathway | Cell Death Discovery - Nature.com
Interleukin-1β induces and accelerates human endometrial stromal cell senescence and impairs decidualization via the c-Jun N-terminal kinase pathway | Cell Death Discovery Nature.com
Published: June 15, 2024, 7 a.m.
Link copied to clipboard!